Sustained high-level expression of full-length human factor VIII and restoration of clotting activity in hemophilic mice using a minimal adenovirus vector

Blood

Volumn 95, Issue 3, 2000, Pages 820-828

  Balagué, Cristina ^b   Zhou, Jiemin ^b   Dai, Yifan ^b   Alemany, Ramón ^b   Josephs, Steven F ^b   Andreason, Grai ^b   Hariharan, Mangala ^b   Sethi, Erica ^b   Prokopenko, Elena ^b   Jan, Hsing Yi ^b   Lou, Yan Chun ^b   Hubert Leslie, Debbie ^b   Ruiz, Lulio ^b   Zhang, Wei Wei ^a  

^a GenStar Therapeutics Corporation   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT BLOOD CLOTTING FACTOR 8; VIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD CLOTTING; CONTROLLED STUDY; GENE EXPRESSION; GENE THERAPY; HEMOPHILIA A; HISTOPATHOLOGY; IMMUNOBLOTTING; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSGENE;

EID: 12944317288     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v95.3.820.003k32_820_828     Document Type: Article

References (37)

1. Ginsburg D. Hemophilias and other disorders of hemostasis. In: Rimoin DL, Connor JM, Pyeritz RE, eds. Principles and Practice of Medical Genetics. Vol. II, 3rd ed. New York: Churchill Livingstone; 1997:1651-1674.
2. Furie B, Limentani SA, Rosenfield CG. A practical guide to the evaluation and treatment of hemophilia. Blood. 1994;84:3-9.
3. Hoyer LW. Hemophilia A. N Engl J Med. 1994;330: 38-47.
4. Dwarki VJ, Belloni P, Nijjar T, et al. Gene therapy for hemophilia A: production of therapeutic levels of human factor VIII in vivo in mice. Proc Natl Acad Sci U S A. 1995;92:1023-1027.
5. Chuah MKL. Vandendriessche T, Morgan RA. Development and analysis of retroviral vectors expressing human factor VIII as a potential gene therapy for hemophilia A. Hum Gene Ther. 1995; 6:1363-1377.
6. Chuah MKL, Brems H, Vanslembrouck V, Collen D, Vandendriessche T. Bone marrow stromal cells as targets for gene therapy of hemophilia A. Hum Gene Ther. 1998;9:353-365.
7. Zatloukal K, Cotten M, Berger M, Schmidt W, Wagner E, Birnstiel ML. In vivo production of human factor VIII in mice after intrasplenic implantation of primary fibroblasts transfected by receptor-mediated, adenovirus-augmented gene delivery. Proc Natl Acad Sci U S A. 1994;91:5148-5152.
8. Connelly S, Smith TAG, Dhir G, et al. In vivo gene delivery and expression of physiological levels of functional human factor VIII in mice. Hum Gen Ther. 1995;6:185-193.
9. Connelly S, Mount J, Mauser A, et al. Complete short-term correction of canine hemophilia A by in vivo gene therapy. Blood. 1996;88:3846-3853.
10. Connelly S, Gardner JM, McClelland A, Kaleko M. High-level tissue-specific expression of functional human factor VIII in mice. Hum Gene Ther. 1996;183-195.
11. Connelly S, Gardner JM, Lyons RM, McClelland A, Kaleko M. Sustained expression of therapeutic levels of human factor VIII in mice. Blood. 1996; 87:4671-4677.
12. Connelly S, Andrews JL, Gallo AM, et al. Sustained phenotypic correction of murine hemophilia A by in vivo gene therapy. Blood. 1998;91: 3273-3281.
13. Vrancken Peeters M-J, Lieber A, Perkins J, Kay MA. Method for multiple portal vein infusions in mice: quantitation of adenovirus-mediated hepatic gene transfer. Biotechniques. 1996;20:278-285.
14. Huard J, Lochmüller H, Acsadi G, Massie B, Karpati G. The route of administration is a major determinant of the transduction efficiency of rat tissues by adenoviral recombinants. Gene Ther. 1995;2:107-115.
15. Li Q, Kay MA, Finegold M, Stratford-Perricaudet LD, Woo SLC. Assessment of recombinant adenoviral vectors for hepatic gene therapy. Hum Gene Ther. 1993;4:403-409.
16. Wion KL, Kelly D, Summerfield JA, Tuddenham EGD, Lawn RM. Distribution of factor VIII mRNA and antigen in human liver and other tissues. Nature. 1985;317:726-729.
17. Zelechowska MG, van Mourik JA, Brodniewicz-Proba T. Ultrastructural localization of factor VIII procoagulant antigen in human liver hepatocytes. Nature. 1985;317:729-730.
18. Pittman DD, Alderman EM, Tomkinson KN, Wang JH, Giles AR, Kaufman RJ, Biochemical, immunological and in vivo functional characterization of B-domain-deleted factor VIII. Blood. 1993;81: 2925-2935.
19. Yang Y, Nunes FA, Berensci K, Furth EE, Gonzol E, Wilson JM. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc Natl Acad Sci U S A. 1994;91:4407-4411.
20. Lieber A, He C-Y, Meuse L, et al. The role of Kupffer cell activation and viral gene expression in early liver toxicity after infusion of recombinant adenovirus vectors. J Virol. 1997;71:8798-8807.
21. Alemany R, Dai Y, Lou YC, et al. Complementation of helper-dependent adenoviral vectors: size effects and titer fluctuations. J Virol Methods. 1997;68:147-159.
22. Lieber A, He C, Kirillova I, Kay MA. Recombinant adenoviruses with large deletions generated by Cre-mediated excision exhibit different biological properties compared with first-generation vectors in vitro and in vivo. J Virol. 1996;70:8944-8960.
23. Parks RJ, Chen L, Anton M, Sankar U, Rudnicki MA, Graham FL. A helper-dependent adenovirus vector system: removal of helper virus by Cre-mediated excision of the viral packaging signal. Proc Natl Acad Sci U S A. 1996;93:13,565-13,570.
24. Kochanek S, Clemens PR, Mitani K, Chen HH, Chan S, Caskey CT. A new adenoviral vector: replacement of all viral coding sequences with 28 Kb of DNA independently expressing both full-length dystrophin and beta-galactosidase. Proc Natl Acad Sci U S A. 1996;93:5731-5736.
25. Kumar-Singh R, Chamberlain JS. Encapsidated adenovirus minichromosomes allow delivery and expression of a 14 Kb dystrophin cDNA to muscle cells. Hum Mol Genet. 1996;5:913-921.
26. Dion LD, Fang J, Garver RI Jr. Supernatant rescue assay vs. polymerase chain reaction for detection of wild type adenovirus-contaminating recombinant adenovirus stocks. J Virol Methods. 1996;56:99-107.
27. Bi L, Lawlwer AM, Antonarakis SE, High KA, Gearhart JD, Kazazian HH Jr. Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A. Nat Genet. 1995;10:119-121.
28. Hayashi Y, Chan J, Nakabayashi H, Hashimoto T, Tamaoki T. Identification and characterization of two enhancers of the human albumin gene. J Biol Chem. 1992;267:14,580-14,585.
29. Parks RJ, Graham FL. A helper-dependent system for adenovirus vector production helps define a lower limit for efficient DNA packaging. J Virol. 1997;71:3293-3298.
30. Chen H-H, Mack LM, Chol S-Y, Ontell M, Kochanek S, Clemens PR. DNA from both high-capacity and first-generation vectors remains intact in skeletal muscle. Hum Gene Ther. 1999;10: 365-373.
31. Lieber A, He C-Y, Kay MA. Adenoviral preterminal protein stabilizes mini-adenoviral genomes in vitro and in vivo. Nat Biotech. 1997;15:1383-1387.
32. Chen H, Mack LM, Kelly R, Ontell M, Kochanek S, Clemens PR. Persistence in muscle of an adenoviral vector that lacks all viral genes. Proc Natl Acad Sci U S A. 1997;94:1645-1650.
33. Schiedner G, Morral N, Parks RJ, et al. Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity. Nat Genet. 1998;18: 180-183.
34. Morsy MA, Gu MC, Motzel S, et al. An adenoviral vector deleted for all viral coding sequences results in enhanced safety and extended expression of a leptin transgene. Proc Natl Acad Sci U S A. 1998; 95:7866-7871.
35. Connelly S, Andrews JL, Gallo-Penn AM, Tagliavacca L, Kaufman RJ, Kaleko M. Evaluation of an adenoviral vector encoding lull-length human factor VIII in hemophilic mice. Thromb Haemost. 1999;81:234-239.
36. Gao G-P, Yang Y, Wilson JM. Biology of adenovirus vectors with E1 and E4 deletions for liver-directed gene therapy. J Virol. 1996;70:8934-8943.
37. Lieber A, He C-Y, Meuse L, Himeda C, Wilson C, Kay M. Inhibition of NF-kB activation in combination with Bcl-2 expression allows for persistence of first-generation adenovirus vectors in the mouse liver. J Virol. 1998;72:9267-9277.